These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 26286301)

  • 21. Appropriate Implantable Defibrillator Therapy in Adults With Hypertrophic Cardiomyopathy.
    Thavikulwat AC; Tomson TT; Knight BP; Bonow RO; Choudhury L
    J Cardiovasc Electrophysiol; 2016 Aug; 27(8):953-60. PubMed ID: 27138377
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hypertrophic cardiomyopathy and sudden death: new perspectives on risk stratification and prevention with the implantable cardioverter-defibrillator.
    Maron BJ
    Eur Heart J; 2000 Dec; 21(24):1979-83. PubMed ID: 11102243
    [No Abstract]   [Full Text] [Related]  

  • 23. Evaluating and Reducing the Risk of Sudden Death in Hypertrophic Cardiomyopathy.
    Udelson JE
    Circulation; 2019 Feb; 139(6):727-729. PubMed ID: 30715941
    [No Abstract]   [Full Text] [Related]  

  • 24. [Primary prevention of sudden cardiac death in 2003. Role of implantable automatic defibrillators].
    Mélon P
    Rev Med Liege; 2003 Jun; 58(6):396-9. PubMed ID: 12945238
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [New strategies for assessing the risk of sudden cardiac death in hypertrophic cardiomyopathy].
    Jaworski K; Możeńska O; Kosior DA
    Pol Merkur Lekarski; 2016 Aug; 41(242):65-9. PubMed ID: 27591441
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transatlantic differences in assessment of risk of sudden cardiac death in patients with hypertrophic cardiomyopathy.
    Jahnlová D; Tomašov P; Zemánek D; Veselka J
    Int J Cardiol; 2015; 186():3-4. PubMed ID: 25804453
    [No Abstract]   [Full Text] [Related]  

  • 27. Hypertrophic Cardiomyopathy: New Evidence Since the 2011 American Cardiology of Cardiology Foundation and American Heart Association Guideline.
    Fraiche A; Wang A
    Curr Cardiol Rep; 2016 Jul; 18(8):70. PubMed ID: 27294414
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Implantable cardioverter defibrillators for primary prevention of sudden death in hypertrophic cardiomyopathy.
    Konstantinou DM; Efthimiadis GK; Vassilikos V; Paraskevaidis S; Pagourelias E; Maron BJ; Karvounis H
    J Cardiovasc Med (Hagerstown); 2016 Jun; 17(6):433-9. PubMed ID: 26885981
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevention of sudden cardiac death in hypertrophic cardiomyopathy.
    O'Mahony C; Elliott PM
    Heart; 2014 Feb; 100(3):254-60. PubMed ID: 23574968
    [No Abstract]   [Full Text] [Related]  

  • 30. Comparison of the new risk prediction model (HCM Risk-SCD) and classic risk factors for sudden death in patients with hypertrophic cardiomyopathy and defibrillator.
    Ruiz-Salas A; García-Pinilla JM; Cabrera-Bueno F; Fernández-Pastor J; Peña-Hernández J; Medina-Palomo C; Barrera-Cordero A; De Teresa E; Alzueta J
    Europace; 2016 May; 18(5):773-7. PubMed ID: 25855675
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hypertrophic cardiomyopathy: ask athletes these 9 questions.
    deWeber K; Beutler A
    J Fam Pract; 2009 Nov; 58(11):576-84. PubMed ID: 19891935
    [No Abstract]   [Full Text] [Related]  

  • 32. Athletes with implantable cardioverter defibrillators: can they return to competitive sports?
    Prutkin JM; Ackerman MJ; Drezner JA
    Heart; 2016 Jan; 102(2):93-4. PubMed ID: 26729607
    [No Abstract]   [Full Text] [Related]  

  • 33. Implantable defibrillators and prevention of sudden death in hypertrophic cardiomyopathy.
    Maron BJ; Spirito P
    J Cardiovasc Electrophysiol; 2008 Oct; 19(10):1118-26. PubMed ID: 18384577
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Implantable defibrillators in long QT syndrome, Brugada syndrome, hypertrophic cardiomyopathy, and arrhythmogenic right ventricular cardiomyopathy.
    Dohadwala M; Link MS
    Cardiol Clin; 2014 May; 32(2):305-18. PubMed ID: 24793806
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Implantable cardioverter-defibrillator implantation for primary and secondary prevention: indications and outcomes.
    Pick JM; Batra AS
    Cardiol Young; 2017 Jan; 27(S1):S126-S131. PubMed ID: 28084973
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Contemporary considerations for risk stratification, sudden death and prevention in hypertrophic cardiomyopathy.
    Maron BJ
    Heart; 2003 Sep; 89(9):977-8. PubMed ID: 12922995
    [No Abstract]   [Full Text] [Related]  

  • 37. My approach to clinical management of hypertrophic cardiomyopathy.
    Maron MS
    Trends Cardiovasc Med; 2014 Oct; 24(7):314-5. PubMed ID: 25218674
    [No Abstract]   [Full Text] [Related]  

  • 38. "Ten Commandments" of 2015 European Society of Cardiology Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death.
    Mazzanti A
    Eur Heart J; 2015 Nov; 36(41):2759. PubMed ID: 27144248
    [No Abstract]   [Full Text] [Related]  

  • 39. [Hypertrophic cardiomyopathy and sudden cardiac death--ICD indications in the margin of uncertainty].
    Fauchère I; Duru F
    Praxis (Bern 1994); 2009 Aug; 98(17):941-52. PubMed ID: 19711287
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Prevention of sudden death with the implantable defibrillator in hypertrophic cardiomyopathy].
    Maron BJ
    Rev Esp Cardiol; 2006 Jun; 59(6):527-30. PubMed ID: 16790193
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.